Japan Oncology Drugs Market Analysis Report 2022 to 2030

Japan Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Japan oncology drugs market will reach a value of $30.4 Bn from $12.2 Bn in 2022, growing at a CAGR of 12.1% during 2022-30. The companies operating in the oncology drug in Japan market are Taiho Pharmaceutical Group, Daiichi Sankyo, and Kyowa Kirin. The Japan oncology drugs market is segmented based on therapy modality and types of cancer. The main drivers of the growth of the Japanese oncology drugs market are the rise in cancer incidence, the explosion in research into new drugs for cancer treatment, and the rise in healthcare spending.

ID: IN10JPPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan

Buy Now

Japan Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the Japan oncology drugs market will reach a value of $30.4 Bn from $12.2 Bn in 2022, growing at a CAGR of 12.1% during 2022-30. Japan's oncology drug market is expanding quickly, which has led to a demand for more creative solutions. Japan spends less on healthcare than other developed nations do, so treatments for diseases like cancer are less expensive and efficient. The lack of modern cancer treatments in Japan restricts your options and your capacity to combat the disease. Due to this restriction, many cancer patients in Japan seek care outside of the country's public healthcare system. This is unfortunate because cancer is still very common in Japan, despite the country's reputation for having a generally healthy society.

7.3% of all healthcare resources are spent on cancer treatment In Japan, which is higher than in other countries. The expenditure on cancer drugs in Japan is $57 per capita, which is lower than in the US ($64) and France ($69), but higher than in the remaining countries.

Japan Oncology Drugs Market Analysis

Market Dynamics

Market Growth Drivers Analysis

More people are able to access life-saving treatments and medications as a result of the rising prevalence of cancer and other related diseases, as well as the rising affordability of these drugs

Prostate and lung cancer therapeutics will dominate the market for cancer medications in Japan in the coming years, largely as a result of the country's sizable geriatric population.

By providing a supportive policy framework for simple drug approval, production, and product marketing, the Japanese government will also play a significant part in the rapid growth of the cancer drug market. It is necessary to alter the policy framework in order to streamline the drug approval process so that internationally accessible products from top MNCs can enter the Japanese market and are easily available to the desired targeted population.

Soon, the Pharmaceuticals and Medical Devices Agency (PMDA) will approve a number of new medications that target various cancer types, expanding the market for these medications. In Japan, there are currently 1617 cancer-related clinical trials being conducted involving more than 350 cancer medications, with about 30% of these trials being in the late stages of development.

Competitive Landscape

Key Players

Taiho Pharmaceutical Group (JPN)
Daiichi Sankyo (JPN)
Kyowa Kirin (JPN)
Otsuka Pharmaceutical Co., Ltd. (JPN)
Celgene Corp
F. Hoffmann-La Roche Ltd
Novartis AG
Bristol-Myers Squibb Co

Recent Notable Updates

September 2022: With the approval of the blood cancer drug Ezharmia, or valemetostat (DS-3201), for the treatment of adult T-cell leukemia/lymphoma (ATL), Daiichi Sankyo achieves a first for the industry.

Healthcare Policies and Regulatory Landscape

Japan's Ministry of Health, Labor, and Welfare (MHLW) is the regulatory body that oversees food and drugs in Japan, which includes creating and implementing safety standards for medical devices and drugs. PMDA (Pharmaceuticals and Medical Devices Agency) is a Japanese regulatory agency, working together with the Ministry of Health, Labour, and Welfare.

Unfortunately, not every treatment is covered by the government-run healthcare system. You must locate the treatment at a clinic unaffiliated with the Japanese healthcare system, pay out of pocket, or make use of private insurance for specific cancer treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.